Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
2,230 total articles
Lear is an unglamorous business in a cyclical industry, but the numbers suggest it’s being priced like a permanent value trap. With LEA around $119.91, a ~14x P/E, EV/EBITDA near 5.6, and strong free cash flow ($734.8M), the risk-reward looks attractive for a mid-term move back toward recent highs, as long as the stock can hold key support near $11…
Ambarella is positioning itself as a picks-and-shovels provider for “physical AI” - on-device perception and decision-making in cameras, automotive, and robotics. CES 2026’s CV7 launch (4nm, multi-sensor 8K, higher AI throughput at lower power) is a timely catalyst, and the stock is back near support after a multi-month slide. This trade idea looks…
KKR has sold off to $121.25 with RSI near 36 and price sitting well below key moving averages. That’s the setup. Under the hood, this is a scaled alternative-asset platform with an insurance leg, solid free cash flow ($5.09B), and a $108B market cap that’s pricing in a lot of macro fear. I’m upgrading the view and looking for a mid-term rebound tow…
Vishay (VSH) is a behind-the-scenes supplier of power semis and passive components that show up in industrial power supplies, EV/HEV systems, telecom gear, and more. The stock just pulled back to ~$18.45 after a sharp run, but the trend remains constructive with bullish momentum signals and a clear near-term catalyst on 02/04/2026 (Q4 and FY2025 re…
Robotaxi headlines have pressured sentiment around Uber, but the economics point to a slower, multi-player rollout where demand aggregation, pricing, and marketplace liquidity still matter. With shares around $82 and technicals washed out, this sets up a mid-term long trade toward a reclaim of key moving averages, with clearly defined risk below re…
Abbott just printed a painful post-earnings air pocket and tagged a fresh 52-week low near $105.78. The selloff looks more like a reset of expectations than a permanent impairment: ABT still carries strong profitability (ROE ~27%), low leverage (debt-to-equity ~0.25), and meaningful free cash flow (~$6.9B). With RSI deeply oversold (~16) and heavy …
LLY sold off after an FDA timing delay for its oral GLP-1, and the tape is now treating that as a bigger competitive loss to Novo than it likely is. With the stock sitting near its 10- and 50-day averages and momentum washed out, the setup favors a defined-risk long trade into a potential sentiment rebound and upcoming catalyst window.
CBL has slipped from its recent high and is now trading below short-term moving averages with a subdued RSI. For a mall REIT with a single-digit P/E, mid-single digit dividend yield, and meaningful free cash flow, that pullback looks more like a reset than a breakdown. This is a mid term trade idea built around mean reversion back toward the 20-day…
Satellogic just printed a new 52-week high on heavy volume, and the tape is finally paying attention to its low-cost Earth observation pitch. Even after the spike, the market cap sits around $710M, while the company is pointing toward higher-resolution NextGen satellites and distribution partnerships that can widen demand. This is a momentum-plus-c…
NeoGenomics sits in a sweet spot of cancer testing: it is big enough to be embedded across community oncology workflows, but still small enough that sentiment can swing fast. With shares around $12.82, improving trend signals (RSI 56, price above key moving averages) and meaningful short interest (about 7.9M shares, ~4.9 days to cover), NEO looks s…
Hims & Hers (HIMS) has gone from market darling to market punching bag in less than a year, sliding from a $72.98 high to the high $20s. But the selloff is starting to look more like a reset than a terminal breakdown: RSI is oversold-ish (34.6), price is extended below key moving averages, and short interest remains heavy (67.1M shares as of 12/31/…
RingCentral has been left for dead after a long grind lower, but at roughly $2.3B in market cap and under 1x sales, the stock is priced like a low-growth melting ice cube. The numbers argue otherwise: the business is still generating meaningful free cash flow ($573M) and trades at just ~4x free cash flow. With RSI in the low-40s and heavy short pos…
Duolingo has the profile of a long-term compounder hiding inside a stock that just went through a violent derating. Shares recently printed a 52-week low near $142 and have started to stabilize around $157, with momentum still bruised but selling pressure showing signs of fatigue. Fundamentally, the market still values DUOL like a real business: ro…
Exail Technologies sits at the intersection of unmanned systems, sensors and mission autonomy — a category benefiting from elevated European defense budgets and a strategic push to localize critical defense technology. This trade targets a move higher as procurement timelines accelerate and commercial partnerships convert into recurring revenue.
Amerigo Resources (ARREF) is a niche copper producer with a growing contribution from electrolytic copper operations. That technical pivot, plus tight free cash flow dynamics and potential commodity tailwinds, creates a setup for a tactical long. Entry at $0.80, stop at $0.55, target $1.50 — position-sized for volatility.
Bristol Myers Squibb (BMY) has seen a rapid rerating. The stock now trades at about $54.65 with a 4.5% yield and a mid-teens PE, but elevated leverage, mixed technicals, and limited near-term growth catalysts argue against further multiple expansion. We downgrade to a short trade for the swing-term (45 trading days) with a clear entry, stop and tar…
GitLab is being punished by a narrative that AI makes developers (and DevSecOps platforms) less valuable. But GitLab’s platform sits in the workflow where AI-created code still has to be secured, reviewed, tested, and deployed. With GTLB down near the low end of its 52-week range and technical momentum turning, this is a clean mid-term rebound trad…
Xiaomi’s ADR (XIACY) is sitting near fresh 52-week lows after a steady momentum unwind. With RSI near 39, price below key moving averages, and bearish MACD still fading, the setup looks less like “catch a falling knife” and more like “wait for stabilization, then rent the rebound.” This trade idea looks for a mean-reversion bounce back toward the 2…
Dino Polska has been a rare European retail growth story, but the setup can flip quickly if union pressure turns into wage inflation, store disruption risk, or a political headline cycle. With limited near-term data to lean on here, this is primarily a sentiment and technical-risk trade: fade a breakdown if labor headlines intensify and price confi…
Sterling Infrastructure (STRL) is a construction solutions provider with a fast-growing E-Infrastructure business that directly benefits from data center and e-commerce buildouts. The stock is down from recent highs and volatile, but momentum remains constructive (bullish MACD, RSI near 59) and the company’s profitability metrics (ROE ~30%, low deb…
Zoetis has drifted down toward the lower end of its 52-week range while key quality signals remain intact: strong profitability metrics, solid liquidity, and a defensible animal health franchise. With bearish momentum showing signs of exhaustion, the setup favors a defined-risk long trade aimed at a rebound back toward key moving averages and prior…
MercadoLibre has pulled back sharply from its 52-week highs even as its core model (commerce plus payments) continues to scale and throw off meaningful free cash flow. With bullish momentum indicators, manageable short interest, and a valuation that still reflects quality but not euphoria, MELI sets up as a mid-term long if it can hold key support …
Modine is still priced like a premium industrial, but the premium is increasingly tied to mix shift toward higher-value thermal solutions, especially data center cooling. With bullish momentum returning and a clear technical line in the sand, this sets up as a mid-term long where you’re betting on sustained AI-driven cooling demand and continued ma…
Axsome Therapeutics is pushing back toward its 52-week high as momentum stays bullish and the market leans into an April 2026 FDA decision for AXS-05 in Alzheimer’s agitation. The stock is not cheap on sales, but the setup is actionable: buy a controlled pullback with a tight stop, aiming for a retest and potential breakout of the $191.50 high. The…
Cal-Maine Foods (CALM) is trading around $80 with a compressed valuation, zero debt-to-equity, and unusually strong liquidity. With earnings approaching and management expanding prepared foods capacity, the setup favors a defined-risk long trade that targets a move back toward key moving averages while respecting the stock’s commodity-like volatili…
